現實世界證據 (RWE) 解決方案市場 - 趨勢分析，競爭市場佔有率，預測:2016年∼2026年
Real-world evidence solution market, By value ; By Therapeutic Area ; By component ; By End User ; By Region ; Trend Analysis, Competitive Market Share & Forecast, 2016-2026.
|出版商||Blueweave Consulting & Research Private Limited||商品編碼||986281|
|出版日期||內容資訊||英文 178 Pages
|現實世界證據 (RWE) 解決方案市場 - 趨勢分析，競爭市場佔有率，預測:2016年∼2026年 Real-world evidence solution market, By value ; By Therapeutic Area ; By component ; By End User ; By Region ; Trend Analysis, Competitive Market Share & Forecast, 2016-2026.|
|出版日期: 2020年09月01日||內容資訊: 英文 178 Pages||
全球現實世界證據 (RWE) 解決方案市場，近幾年增加氣勢，預計至2026年達到33億2,170萬美元，2020年∼2026年以16.5％的年複合成長率成長。
本報告提供全球現實世界證據 (RWE) 解決方案市場調查分析，市場概要，各地區的市場規模與預測，競爭情形，主要企業等相關的系統性資訊。
Real-world evidence solution market, By value (Market share and forecast); By Therapeutic Area (cardiovascular, oncology, immunology, others); By component (Dataset, Clinical setting data, Claims data, Pharmacy Data, Patient-Powered Data); By End User (Medical Devices, Players, Pharmaceuticals, Providers); By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa); Trend Analysis, Competitive Market Share & Forecast, 2016-2026..
Global Real-World Evidence Solutions market has gained momentum in recent years with a CAGR of 16.5%, in value terms, over the forecast period 2020-2026, and is expected to reach USD 3,321.7 million by 2026. The growth is due to the shift from volume to value-based care, increasing aging population and prevalence of chronic diseases and delays in drug development, and the subsequent increase in development costs. Besides, the real-world data sets are widely adopted by end-users for RWE for various applications such as drug development & approvals, market access & reimbursement/coverage decisions, clinical decision-making, and medical device development & approvals, among others, that helps in the growth of the overall market.
Based on the therapeutic area, the real-world evidence market is broadly categorized into oncology, immunology, neurology, cardiovascular disease, and other therapeutic areas the oncology segment has been accounted for the largest share of the real-world evidence market. The large share of this segment can be attributed to the high number of clinical trials conducted for oncology and the rising prevalence of cancer worldwide. According to the World Health Organization (WHO), Cancer is the second leading cause of death across the globe, with an estimated 9.6 million deaths in 2018. There is also an increasing personalized medicine and a more precise requirement for oncology, which is expected to further fuel the market growth.
A rise in investment creates new opportunities in the market. For instance, Syapse, a San Francisco, CA-based provider of precision oncology solutions announced USD 30 million in new equity funding to accelerate the creation and use of real-world evidence (RWE) in oncology led by Revelation Alpine, LLC, with participation from existing investors including Amgen Ventures, Ascension Ventures, Intermountain Ventures, Merck Global Health Innovation Fund, Roche Finance Ltd, Safeguard Scientifics and Social Capital. Revelation Alpine's Managing Partner Zack Scott, MD will join the Syapse Board of Directors. Syapse collaborates with life sciences companies to provide insights from real-world data through its portfolio of products to support research and product development, clinical trials patient matching, real-world evidence regulatory filings, and monitoring of commercially approved products. Syapse supports health systems with insights to support health systems' large-scale precision medicine programs through integrating the clinical, molecular, and outcomes data they need to make the most informed treatment decisions.
North America accounted for the largest share of the real-world evidence market in 2019, followed by Europe and the Asia Pacific. The presence of a favorable regulatory environment, a high number of RWE service providers, the presence of a well-established pharmaceutical industry in the region, coupled with the high R&D expenditure, are the major factors responsible for the large share of North America in the global real-world evidence market. The US is expected to dominate the North American market, owing to a high demand in clinical research activities, which is one of the important factors augmenting the demand for real-world evidence solutions market in the North America region.
Key players for Real World Evidence Solutions Market: Anthem, Inc., Clinigen Group plc, Cognizant Technology Solutions Corporation, International Business Machines (IBM) Corporation, ICON Public Limited, Quintiles IMS Holdings, Inc., UnitedHealth Group, Oracle Corporation, PAREXEL International Corporation, PerkinElmer, Inc., and other Prominent Players.
Anthem - The company offers and generates consistent and actionable evidence to support decision making while helping to guide fresh initiatives for a range of stakeholders in the healthcare industry through wholly-owned health outcomes research subsidiary, HealthCore, Inc. HealthCore, Inc. operates through three divisions namely, life science companies, government & academia, and payers & providers.